skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
c-Met Inhibitor JNJ-38877605 (Code C77893)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: c-Met Inhibitor JNJ-38877605

Definition: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).

Label: c-Met Inhibitor JNJ-38877605

NCI Thesaurus Code: C77893 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL383572  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
c-Met Inhibitor JNJ-38877605

External Source Codes: 
PDQ Closed Trial Search ID 594157
PDQ Open Trial Search ID 594157 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C77893
Legacy_Concept_Name c-Met_Inhibitor_JNJ-38877605
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom